Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum cytokine IL-8 levels as predictors of aflibercept + FOLFIRI efficacy in metastatic colorectal cancer
2017-003509-16Phase 4Completed
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jan 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of aflibercept in metastatic colon cancer (mCRC) (2 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Progression-free survival. Started Jan 2022; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2017-003509-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003509-16.